PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with Gerresheimer AG (MDAX: GXI) and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ('Alliance for RTU') to support market adoption of Ready-to-Use (RTU) vials and cartridges..

意大利PIOMBINO DESE——（商业新闻短讯）——Stevanato Group S.p.A.（纽约证券交易所：STVN），一家为制药、生物技术和生命科学行业提供药物遏制、药物输送和诊断解决方案的全球领先供应商，与Gerresheimer AG（MDAX:GXI）和SCHOTT Pharma AG＆Co.KGaA（MDAX:1SXP）今天宣布，他们已加入战略产业联盟（“RTU联盟”），以支持市场采用即用（RTU）小瓶和药筒。。

The Alliance for RTU aims to share with pharmaceutical companies, CMOs and CDMOs expertise and technical knowledge in high-quality sterile primary packaging, specifically ready-to-fill vials and cartridges, highlighting RTU configurations' advantages over conventional bulk packaging.

RTU联盟旨在与制药公司分享CMOs和CDMOs在高质量无菌初级包装方面的专业知识和技术知识，特别是即装小瓶和药筒，突出RTU配置相对于传统散装包装的优势。

Reduced risks and lower total cost of ownership

降低风险，降低总体拥有成本

Traditional fill&finish processes present several operational risks and require increased efficiency. By adopting an industrial ready-to-use (RTU) setup, pharmaceutical companies and Contract Manufacturing Organizations (CMOs) can benefit from reduced operational risks, enhanced flexibility and efficiency, and lower waste.

传统的填充和精加工工艺存在一些操作风险，需要提高效率。通过采用工业即用（RTU）设置，制药公司和合同制造组织（CMO）可以从降低运营风险，提高灵活性和效率以及减少浪费中受益。

RTU technology can help streamline processes, increase productivity, and thus lower total cost of ownership (TCO) while reducing contamination risks and easing EU GMP Annex 1 compliance..

RTU技术有助于简化流程，提高生产率，从而降低总拥有成本（TCO），同时降低污染风险，缓解欧盟GMP附件1的合规性。。

Pharmaceutical companies, CMOs and CDMOs opting for ready-to-use containers also can benefit from higher-quality products, which helps minimize the release of glass particles and risks of breakage or rejection while preserving the drug inside throughout its entire life cycle.

选择即用容器的制药公司、CMOs和CDMOs也可以从更高质量的产品中受益，这有助于最大程度地减少玻璃颗粒的释放和破裂或排斥的风险，同时在整个生命周期中将药物保存在内部。

Open expert platform for RTU industry standard

RTU行业标准开放式专家平台

Additionally, the market is driving investment in advanced aseptic filling technologies due to increasing demand for injectable medicines and regulatory pressure to meet safety standards. In this context, the Alliance for RTU aims to create an expert platform open to other industry players to help industry manufacturers learn about the key benefits of RTU processes and products and to better evaluate investments for transitioning to efficient filling systems and meeting their unique needs from clinical applications to widespread commercial use..

此外，由于对注射用药物的需求不断增加以及满足安全标准的监管压力，市场正在推动对先进无菌灌装技术的投资。在这种情况下，RTU联盟旨在创建一个向其他行业参与者开放的专家平台，以帮助行业制造商了解RTU工艺和产品的关键好处，并更好地评估向高效填充系统过渡的投资，并满足其从临床应用到广泛商业用途的独特需求。。

“RTU vials and cartridges represent a significant advancement in product quality, offering enhanced reliability and efficiency in pharmaceutical processes. This alliance allows us to highlight further how RTU solutions elevate standards across the industry, ensuring safer and more effective delivery of medications to patients worldwide,' said Franco Stevanato, CEO at Stevanato Group..

Stevanato Group首席执行官Franco Stevanato说：“RTU小瓶和药筒代表了产品质量的重大进步，提高了制药过程的可靠性和效率。这一联盟使我们能够进一步强调RTU解决方案如何提高整个行业的标准，确保更安全、更有效地向全球患者提供药物。”。。

“The shift towards ready-to-use vials and cartridges reflects a collective industry move to advance quality and efficiency in aseptic filling processes and this alliance shows readiness by expanding capacity and thereby supporting this market trend,” said Andreas Reisse, CEO at SCHOTT Pharma. “Ready-to-use solutions can reduce complexities and better meet the stringent requirements of modern pharmaceutical production.”.

肖特制药（SCHOTT Pharma）首席执行官安德烈亚斯·赖斯（Andreas Reisse）表示：“向即用小瓶和药筒的转变反映了行业集体行动，以提高无菌灌装过程的质量和效率，这一联盟通过扩大产能，从而支持这一市场趋势，显示了其准备就绪。”。“即用解决方案可以降低复杂性，更好地满足现代制药生产的严格要求。”。

'As an industry, we are fully prepared for the transition to RTU vials and cartridges”, said Lukas Burkhardt, Member of the Management Board of Gerresheimer AG. “With recent advancements, RTU processing is now a mature technology which will improve our customers operations in terms of efficiency, cost and time to market.'.

Gerresheimer AG管理委员会成员卢卡斯·伯克哈特（LukasBurkhardt）表示：“作为一个行业，我们已经为向RTU小瓶和药筒的过渡做好了充分准备。随着最近的进步，RTU处理现在已经成为一种成熟的技术，将在效率、成本和上市时间方面改善我们客户的运营。”。

The Alliance for RTU will be officially presented at the CPHI in Milan on October 8 during a dedicated event at the tradeshow fairground. For more information, visit www.alliance-for-rtu.com.

RTU联盟将于10月8日在米兰的CPHI展会上正式亮相，届时将在贸易展览展场举行专门活动。有关更多信息，请访问www.alliance-For-rtu.com。

About Stevanato Group

关于Stevanato集团

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages.

Stevanato集团成立于1949年，是一家为制药、生物技术和生命科学行业提供药物遏制、药物输送和诊断解决方案的全球领先供应商。该集团提供完整的端到端产品、流程和服务组合，以满足客户在整个药物生命周期的每个开发、临床和商业阶段的需求。

Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com..

Stevanato集团在科学研究和开发方面的核心能力、对技术创新的承诺以及卓越的工程技术是其向客户提供增值解决方案能力的核心。要了解更多信息，请访问：www.stevanatogroup.com。。

About Gerresheimer

关于Gerresheimer

Gerresheimer is an innovative systems and solutions provider and a global partner to the pharma, biotech, and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry.

Gerresheimer是一家创新系统和解决方案提供商，也是制药、生物技术和化妆品行业的全球合作伙伴。该公司提供全面的药物控制解决方案、药物输送系统和医疗设备以及健康行业解决方案组合。

The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles, and more. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets.

产品范围包括用于治疗支持的数字解决方案、药物泵、注射器、钢笔、自动注射器和吸入器以及小瓶、安瓿、片剂容器、输液器、滴管和糖浆瓶等。Gerresheimer在欧洲、美洲和亚洲的16个国家拥有35个生产基地，业务遍及全球，并在当地为区域市场生产产品。

With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6)..

该公司拥有约12000名员工，2023年的收入约为20亿欧元。Gerresheimer AG在法兰克福证券交易所的MDAX上市（ISIN:DE000A0LD6E6）。。

www.gerresheimer.com

www.gerresheimer.com

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules.

人类健康很重要。。该组合包括用于注射药物的药物遏制解决方案和输送系统，从预填充玻璃和聚合物注射器到药筒，小瓶和安瓿。

Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future.

肖特制药（SCHOTT Pharma）每天都有来自60多个国家的4600多人组成的团队为全球医疗保健做出贡献。该公司在欧洲、北美、南美和亚洲的所有主要制药中心拥有16个生产基地。该公司拥有1000多项内部开发的专利和技术，并在瑞士拥有最先进的研发中心，专注于为未来开发创新。

SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030.

肖特制药股份有限公司KGaA总部位于德国美因茨，作为SDAX的一部分在法兰克福证券交易所上市。它是由卡尔·蔡司基金会拥有的肖特公司的一部分。本着这种精神，肖特制药致力于社会和环境的可持续发展，并制定了到2030年实现气候中性的战略目标。

Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023. Further information at www.schott-pharma.com..

目前，肖特制药拥有1800多家客户，其中包括前30家领先的注射剂制药制造商，2023财年的收入为8.99亿欧元。更多信息请访问www.schott-pharma.com。。

Forward-Looking Statements

前瞻性声明

This press release may include forward-looking statements. The words “aims”, “”increase”, “lower”, “ is driving”, “increasing”, “create”, “move”, “expanding”, “advance”, “can”, “will”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S.

本新闻稿可能包括前瞻性声明。“目标”，“增加”，“降低”，“正在推动”，“增加”，“创造”，“移动”，“扩展”，“前进”，“可以”，“意志”以及类似的表达（或其负面）确定了某些前瞻性陈述。这些前瞻性声明是关于公司的意图、信念或当前期望的声明，其中包括公司预期收到的投资、制造能力的扩大、公司在美国的存在计划。

and other markets, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future.

以及其他市场、业务战略、公司满足未来市场需求和支持未来公共卫生突发事件准备的能力以及运营结果。本新闻稿中的前瞻性陈述基于对公司当前和未来业务战略以及公司未来运营环境的众多假设。

Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking statements.

前瞻性陈述涉及固有的已知和未知风险、不确定性和或有事项，因为它们与事件有关，取决于未来可能发生或不可能发生的情况，并可能导致公司的实际结果、业绩或成就与此类前瞻性陈述明示或暗示的结果、业绩或成就存在重大差异。

Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates o.

其中许多风险和不确定性与公司无法精确控制或估计的因素有关，例如未来市场状况、货币波动、其他市场参与者的行为、监管机构的行动以及其他因素，例如公司继续获得融资以满足其流动性需求的能力、公司运营所在的政治、社会和监管框架的变化。